[1]崔忠泽,何 双,路丽祯,等.基于生物信息学分析筛选结肠癌关键基因[J].医学信息,2022,35(10):1-7.[doi:10.3969/j.issn.1006-1959.2022.10.001]
 CUI Zhong-ze,HE Shuang,LU Li-zhen,et al.Screening Key Genes of Colon Cancer Based on Bioinformatics Analysis[J].Medical Information,2022,35(10):1-7.[doi:10.3969/j.issn.1006-1959.2022.10.001]
点击复制

基于生物信息学分析筛选结肠癌关键基因()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年10期
页码:
1-7
栏目:
生物信息学
出版日期:
2022-05-15

文章信息/Info

Title:
Screening Key Genes of Colon Cancer Based on Bioinformatics Analysis
文章编号:
1006-1959(2022)10-0001-07
作者:
崔忠泽何 双路丽祯
(滨州医学院附属医院病理科,山东 滨州 256600)
Author(s):
CUI Zhong-zeHE ShuangLU Li-zhenet al.
(Department of Pathology,Affiliated Hospital,Binzhou Medical University,Binzhou 256600,Shandong,China)
关键词:
结肠癌免疫相关基因预后相关基因功能富集
Keywords:
Colon cancerImmune-related genesPrognosis-related genesFunctional enrichment
分类号:
R735.3
DOI:
10.3969/j.issn.1006-1959.2022.10.001
文献标志码:
A
摘要:
目的 鉴定可能参与结肠癌发生发展的预后相关枢纽基因和免疫相关基因。方法 从TCGA数据库和GEO数据库(GSE41657、GSE74602、GSE106582和GSE110224)中下载结肠癌数据集,鉴定共同差异表达基因,并对其进行功能富集分析、预后相关基因筛选、免疫相关基因筛选、蛋白相互作用网络构建,进一步分析预后相关枢纽基因和免疫相关基因的表达量、免疫组化和功能富集。结果 共筛选102个共同差异基因,其中预后相关基因15个,免疫相关基因6个,枢纽基因16个,选取预后相关枢纽基因(SLC17A4)和免疫相关基因(NR3C2、ETFDH、SCG2)作为目标基因进一步分析,发现ETFDH主要表达于细胞质,NR3C2在细胞核和细胞质中大量表达,SCG2在细胞质中有少量表达,SLC17A4主要表达于细胞膜,上述基因在癌组织中均低表达,富集分析显示其与诸多结肠癌相关功能关联,其中免疫相关基因与结肠癌免疫密切相关并总体呈正相关。结论 15个预后相关基因有望作为生物标记物来预测结肠癌预后。SLC17A4在结肠癌中作为预后相关枢纽基因可能发挥重要功能,NR3C2、ETFDH、SCG2作为免疫相关预后基因可能在调控结肠癌肿瘤免疫过程中发挥着重要作用,这为探索结肠癌的分子机理提供了新的思路。
Abstract:
Objective To identify the prognostic hub genes and immune related genes that may be involved in the development of colon cancer.Methods The data sets of colon cancer were downloaded from TCGA database and GEO database ( GSE41657, GSE74602, GSE106582 and GSE110224), and the common differentially expressed genes were identified. Functional enrichment analysis, prognosis-related gene screening, immune-related gene screening and protein-protein interaction network construction were performed on the common differentially expressed genes. The expression levels, immunohistochemistry and functional enrichment of prognosis-related hub genes and immune-related genes were further analyzed.Results A total of 102 common differentially expressed genes were screened, including 15 prognostic-related genes, 6 immune-related genes and 16 hub genes. The prognostic-related hub genes (SLC17A4) and immune-related genes (NR3C2, ETFDH, SCG2) were selected as target genes for further analysis. It was found that ETFDH was mainly expressed in the cytoplasm, NR3C2 was highly expressed in the nucleus and cytoplasm, SCG2 was slightly expressed in the cytoplasm, SLC17A4 was mainly expressed in the cell membrane, and the above genes were lowly expressed in cancer tissues. Enrichment analysis showed that they were associated with many colon cancer-related functions. Among them, immune-related genes were closely related to colon cancer immunity and are generally positively correlated.Conclusion Fifteen prognostic genes are expected to be used as biomarkers to predict the prognosis of colon cancer.SLC17A4 may play an important role as a prognostic pivotal gene in colon cancer, while NR3C2, ETFDH and SCG2 as immunorelated prognostic genes may play an important role in the regulation of colon cancer tumor immunity, which provides a new idea for exploring the molecular mechanism of colon cancer.

参考文献/References:

[1]Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA A Cancer J Clin,2021,71(3):209-249.[2]Mauri G,Bonazzina E,Amatu A,et al.The evolutionary landscape of treatment for BRAFV600Emutant metastatic colorectal cancer[J].Cancers (Basel),2021,13(1):E137.[3]Ruffinelli JC,Santos Vivas C,Sanz-Pamplona R,et al.New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients[J].Expert Rev Gastroenterol Hepatol,2021,15(1):65-79.[4]Luo QX,Chen DK,Fan XJ,et al.KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: a single-site report[J].Transl Oncol,2020,13(12):100874.[5]Tao ZQ,Shi AM,Li R,et al.Microarray bioinformatics in cancer- a review[J].J BUON,2017,22(4):838-843.[6]Saito M,Momma T,Kono K.Targeted therapy according to next generation sequencing-based panel sequencing[J].Fukushima J Med Sci,2018,64(1):9-14.[7]Harada K,Okamoto W,Mimaki S,et al.Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy[J].BMC Cancer,2019,19(1):255.[8]Zhao B,Baloch Z,Ma YH,et al.Identification of potential key genes and pathways in early-onset colorectal cancer through bioinformatics analysis[J].Cancer Control,2019,26(1):1073274819831260.[9]Cojocneanu R,Braicu C,Raduly L,et al.Plasma and tissue specific miRNA expression pattern and functional analysis associated to colorectal cancer patients[J].Cancers (Basel),2020,12(4):E843.[10]Kishore C,Bhadra P.Current advancements and future perspectives of immunotherapy in colorectal cancer research[J].Eur J Pharmacol,2021,893:173819.[11]Wu J,Cai JT.Dilemma and challenge of immunotherapy for pancreatic cancer[J].Dig Dis Sci,2021,66(2):359-368.[12]Chakravarty D,Huang L,Kahn M,et al.Immunotherapy for metastatic prostate cancer: current and emerging treatment options[J].Urol Clin North Am,2020,47(4):487-510.[13]Esteva FJ,Hubbard-Lucey VM,Tang J,et al.Immunotherapy and targeted therapy combinations in metastatic breast cancer[J].Lancet Oncol,2019,20(3):e175-e186.[14]Lei X,Lei Y,Li JK,et al.Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy[J].Cancer Lett,2020,470:126-133. [15]Edgar R,Domrachev M,Lash AE.Gene Expression Omnibus: NCBI gene expression and hybridization array data repository[J].Nucleic Acids Res,2002,30(1):207-210.[16]Wang ZN,Jensen MA,Zenklusen JC.A practical guide to the cancer genome atlas (TCGA) [J].Methods Mol Biol,2016,1418:111-141.[17]Kanehisa M.The KEGG database[J].Novartis Found Symp,2002,247:91-252.[18]Ashburner M,Ball CA,Blake JA,et al.Gene ontology: tool for the unification of biology. The Gene Ontology Consortium[J].Nat Genet,2000,25(1):25-29.[19]Tang ZF,Li CW,Kang BX,et al.GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J].Nucleic Acids Res,2017,45(W1):W98-W102.[20]Uhlen M,Zhang C,Lee S,et al.A pathology atlas of the human cancer transcriptome[J].Science,2017,357(6352):eaan2507. [21]Subramanian A,Tamayo P,Mootha VK,et al.Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles[J].Proc Natl Acad Sci U S A,2005,102(43):15545-15550.[22]Hristova VA,Chan DW.Cancer biomarker discovery and translation: proteomics and beyond[J].Expert Rev Proteomics,2019,16(2):93-103.[23]Lu MX,Zhang JX,Zhang LJ.Emerging concepts and methodologies in cancer biomarker discovery[J].Crit Rev Oncog,2017,22(5-6):371-388.[24]Ganesh K,Stadler ZK,Cercek A,et al.Immunotherapy in colorectal cancer: rationale, challenges and potential[J].Nat Rev Gastroenterol Hepatol,2019,16(6):361-375.[25]Johdi NA,Sukor NF.Colorectal cancer immunotherapy: options and strategies[J].Front Immunol,2020,11:1624.[26]Cicatiello AG,Ambrosio R,Dentice M.Thyroid hormone promotes differentiation of colon cancer stem cells[J].Mol Cell Endocrinol,2017,459:84-89.[27]Tian D,Tian M,Han G,et al.Increased glucocorticoid receptor activity and proliferation in metastatic colon cancer[J].Sci Rep,2019,9(1):11257.[28]Deng D,Luo X,Zhang SF,et al.Immune cell infiltration-associated signature in colon cancer and its prognostic implications[J].Aging (Albany NY),2021,13(15):19696-19709.[29]Malka D,Lièvre A,André T,et al.Immune scores in colorectal cancer: where are we? [J].Eur J Cancer,2020,140:105-118.[30]Abdul-Latif M,Townsend K,Dearman C,et al.Immunotherapy in gastrointestinal cancer: the current scenario and future perspectives[J].Cancer Treat Rev,2020,88:102030.[31]Xie P,Mo JL,Liu JH,et al.Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update[J].Cell Oncol (Dordr),2020,43(6):989-1001.[32]Blondy S,David V,Verdier M,et al.5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes[J].Cancer Sci,2020,111(9):3142-3154.[33]Wassenaar TM.E. coli and colorectal cancer: a complex relationship that deserves a critical mindset[J].Crit Rev Microbiol,2018,44(5):619-632.[34]Tang L,Zhou YJ,Zhu SL,et al.E. coli diversity: low in colorectal cancer[J].BMC Med Genomics,2020,13(1):59.[35]Mo A,Jackson S,Varma K,et al.Distinct transcriptional changes and epithelial-stromal interactions are altered in early-stage colon cancer development[J].Mol Cancer Res,2016,14(9):795-804.[36]Liu JH,Jiang CH,Xu CJ,et al.Identification and development of a novel invasion-related gene signature for prognosis prediction in colon adenocarcinoma[J].Cancer Cell Int,2021,21(1):101.[37]Liang B,Zheng B,Zhou Y,et al.Characterization of a tumor-microenvironment-relevant gene set based on tumor severity in colon cancer and evaluation of its potential for dihydroartemisinintargeting[J].Evid Based Complement Alternat Med,2021,2021:4812068.[38]Hardbower DM,Coburn LA,Asim M,et al.EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis[J].Oncogene,2017,36(27):3807-3819.[39]Edin S,Kaprio T,Hagstr?觟m J,et al.The prognostic importance of CD20+ B lymphocytes in colorectal cancer and the relation to other immune cell subsets[J].Sci Rep,2019,9(1):19997.[40]Saito T,Nishikawa H,Wada H,et al.Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers[J].Nat Med,2016,22(6):679-684.[41]O’Malley G,Treacy O,Lynch K,et al.Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer[J].Cancer Immunol Res,2018,6(11):1426-1441. [42]Olesch C,Sirait-Fischer E,Berkefeld M,et al.S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion[J].J Clin Invest,2020,130(10):5461-5476.[43]Mizuno R,Kawada K,Itatani Y,et al.The role of tumor-associated neutrophils in colorectal cancer[J].Int J Mol Sci,2019,20(3):E529.[44]Locati M,Curtale G,Mantovani A.Diversity, mechanisms, and significance of macrophage plasticity[J].Annu Rev Pathol,2020,15:123-147.[45]Isidro RA,Appleyard CB.Colonic macrophage polarization in homeostasis, inflammation, and cancer[J].Am J PhysiolGastrointest Liver Physiol,2016,311(1):G59-G73.[46]Najafi M,Hashemi Goradel N,Farhood B,et al.Macrophage polarity in cancer: A review[J].J Cell Biochem,2019,120(3):2756-2765.

相似文献/References:

[1]苏周荣,杜东霖,魏正强.左半结肠癌伴梗阻一期切除吻合策略研究[J].医学信息,2018,31(10):51.[doi:10.3969/j.issn.1006-1959.2018.10.016]
 SU Zhou-rong,DU Dong-lin,WEI Zheng-qiang.Strategy of One-stage Resection and Anastomosis for Left Colon Cancer with Obstruction[J].Medical Information,2018,31(10):51.[doi:10.3969/j.issn.1006-1959.2018.10.016]
[2]石 磊,孙新增,李宝山,等.Ⅱ、Ⅲ期结肠癌患者辅助化疗XELOX方案、FOLFOX方案的临床疗效、不良反应及生活质量对比[J].医学信息,2018,31(13):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
 SHI Lei,SUN Xin-zeng,LI Bao-shan,et al.Clinical Efficacy,Adverse Reactions and Quality of Life of Adjuvant Chemotherapy XELOX and FOLFOX in Patients with Stage II and III Colon Cancer[J].Medical Information,2018,31(10):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
[3]王 超,范小华,张 力,等.下腔静脉畸形伴腹腔多脏器异位合并结肠癌1例[J].医学信息,2018,31(18):188.[doi:10.3969/j.issn.1006-1959.2018.18.062]
 WANG Chao,FAN Xiao-hua,ZHANG Li,et al.a Case of Inferior Vena Cava Malformation Associated with Multiple Abdominal Organ Ectopic Colon Cancer[J].Medical Information,2018,31(10):188.[doi:10.3969/j.issn.1006-1959.2018.18.062]
[4]操利超,张核子,余晨笛,等.CLDN11在结肠癌中的预后价值及其作为潜在免疫治疗靶点的研究[J].医学信息,2022,35(14):10.[doi:10.3969/j.issn.1006-1959.2022.14.002]
 CAO Li-chao,ZHANG He-zi,YU Chen-di,et al.The Prognostic Value of CLDN11 in Colon Cancer and its Potential Immunotherapy Targets[J].Medical Information,2022,35(10):10.[doi:10.3969/j.issn.1006-1959.2022.14.002]
[5]黄富全.结合靶向药物综合治疗结肠癌肝及肝外转移术后7年1例报告[J].医学信息,2019,32(01):186.[doi:10.3969/j.issn.1006-1959.2019.01.061]
[6]葛菁茹,朱静雅,苏日新,等.以肺转移为首发表现的结肠癌预后分析[J].医学信息,2021,34(04):96.[doi:10.3969/j.issn.1006-1959.2021.04.025]
 GE Jing-ru,ZHU Jing-ya,SU Ri-xin,et al.Prognostic Analysis of Colon Cancer with Lung Metastasis as the First Manifestation[J].Medical Information,2021,34(10):96.[doi:10.3969/j.issn.1006-1959.2021.04.025]
[7]韩 猛,薛三宝,倪 丰.CT与MRI术前诊断结肠癌及评价术后复发的价值[J].医学信息,2021,34(21):175.[doi:10.3969/j.issn.1006-1959.2021.21.050]
 HAN Meng,XUE San-bao,NI Feng.Value of CT and MRI in Preoperative Diagnosis and Postoperative Recurrence of Colon Cancer[J].Medical Information,2021,34(10):175.[doi:10.3969/j.issn.1006-1959.2021.21.050]
[8]操利超,巴 颖,卢晓萍,等.基于TCGA和GEO数据库构建结肠癌预后模型[J].医学信息,2021,34(24):27.[doi:10.3969/j.issn.1006-1959.2021.24.006]
 CAO Li-chao,BA Ying,LU Xiao-ping,et al.Prognostic Model of Colon Cancer Based on TCGA and GEO Database[J].Medical Information,2021,34(10):27.[doi:10.3969/j.issn.1006-1959.2021.24.006]
[9]张秀娟,黄丽娟.mTOR、PTEN、Ki-67蛋白表达水平变化与结肠癌病理学特征的相关性分析[J].医学信息,2022,35(19):54.[doi:10.3969/j.issn.1006-1959.2022.19.014]
 ZHANG Xiu-juan,HUANG Li-juan.Correlation of mTOR, PTEN and Ki-67 Protein Expression with Pathological Features of Colon Cancer[J].Medical Information,2022,35(10):54.[doi:10.3969/j.issn.1006-1959.2022.19.014]
[10]李 洋.北京市海淀区居民结肠癌防治知识知晓情况分析[J].医学信息,2021,34(08):141.[doi:10.3969/j.issn.1006-1959.2021.08.037]
 LI Yang.Analysis of Knowledge About Colon Cancer Prevention and Treatment Among Residents in Haidian District,Beijing[J].Medical Information,2021,34(10):141.[doi:10.3969/j.issn.1006-1959.2021.08.037]

更新日期/Last Update: 1900-01-01